Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Core Viewpoint - Plus Therapeutics reported a quarterly loss of $0.56 per share, significantly worse than the Zacks Consensus Estimate of a loss of$ 0.17, marking an earnings surprise of -229.41% [1] - The company has consistently missed consensus EPS estimates over the last four quarters and reported revenues of $1.06 million, missing the estimate by 42.76% [2] Financial Performance - The loss per share of$ 0.56 is an improvement from a loss of $0.75 per share a year ago [1] - Revenues decreased from$ 1.68 million in the same quarter last year to $1.06 million [2] - Plus shares have declined approximately 75.1% year-to-date, contrasting with the S&P 500's gain of 0.5% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$ 0.17 for the next quarter and -$0.67 for the current fiscal year [7] - The estimate revisions trend for Plus is currently favorable, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - The Medical - Drugs industry, to which Plus belongs, is ranked in the top 28% of Zacks industries, suggesting a positive industry outlook [8]